Drug discovery is known for its high attrition rates that lead to significant investments of both cost and time. But the emergence of patient-derived cells (PDCs) is on track to revolutionise this process, offering a promising route to more efficient and effective drug development.
In this article, Dr Andrew Carnegie, Head of Strategic Commercial Development at Inaphaea, explores the potential of PDCs and their role in shaping the future of drug discovery.